COST-EFFECTIVENESS ANALYSIS OF HISTAMINE DIHYDROCHLORIDE plus LOW DOSE INTERLEUKIN-2 VS STANDARD OF CARE FOR ACUTE MYELOID LEUKEMIA PATIENTS IN THEIR FIRST COMPLETE REMISSION: A UK PERSPECTIVE

被引：1
|
作者：
Magar, R. S. [1 ]
Purdy, C. [2 ]
Hayward, A. [2 ]
Einarson, T. R. [3 ]
Burnett, A. K. [4 ]
机构：
[1] AHRM Inc, Raleigh, NC USA
[2] AHRM Inc, Buffalo, NY USA
[3] Univ Toronto, Toronto, ON, Canada
[4] Cardiff Univ, Cardiff CF4 4XN, S Glam, Wales
来源：
VALUE IN HEALTH | 2009年 / 12卷 / 07期
关键词：
D O I：
10.1016/S1098-3015(10)74334-5
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
下载
收藏
页码：A272 / A272
页数：1
相关论文
共 50 条
  • [1] Histamine dihydrochloride and low-dose interleukin-2 as post-consolidation immunotherapy in acute myeloid leukemia
    Thoren, Fredrik B.
    Romero, Ana I.
    Brune, Mats
    Hellstrand, Kristoffer
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2009, 9 (09) : 1217 - 1223
  • [2] Relapse Prevention in Acute Myeloid Leukemia: The Role of Immunotherapy with Histamine Dihydrochloride and Low-Dose Interleukin-2
    Montesinos, Pau
    Buccisano, Francesco
    Cluzeau, Thomas
    Vennstroem, Lovisa
    Heuser, Michael
    CANCERS, 2024, 16 (10)
  • [3] Immunotherapy with histamine dihydrochloride and low-dose interleukin-2 favors sustained lymphocyte recovery in acute myeloid leukemia
    Hallner, Alexander
    Aurelius, Johan
    Thoren, Fredrik Bergh
    Sander, Frida Ewald
    Brune, Mats
    Hellstrand, Kristoffer
    Martner, Anna
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2015, 94 (03) : 279 - 280
  • [4] Incremental Benefit of Histamine Dihydrochloride When Added to Interleukin-2 for Remission Maintenance In Acute Myeloid Leukemia: A Bayesian Meta-Analysis.
    Berry, Scott M.
    Broglio, Kristine R.
    Berry, Donald A.
    BLOOD, 2010, 116 (21) : 900 - 901
  • [5] Low dose interleukin-2 following intensification therapy with high dose cytarabine for acute myelogenous leukemia in first complete remission
    Stone, Richard M.
    DeAngelo, Daniel J.
    Janosova, Anna
    Galinsky, Ilene
    Canning, Christine
    Ritz, Jerome
    Soiffer, Robert J.
    AMERICAN JOURNAL OF HEMATOLOGY, 2008, 83 (10) : 771 - 777
  • [6] Recombinant Interleukin-2 in Patients Aged Younger Than 60 Years With Acute Myeloid Leukemia in First Complete Remission
    Kolitz, Jonathan E.
    George, Stephen L.
    Benson, Don M., Jr.
    Maharry, Kati
    Marcucci, Guido
    Vij, Ravi
    Powell, Bayard L.
    Allen, Steven L.
    DeAngelo, Daniel J.
    Shea, Thomas C.
    Stock, Wendy
    Bakan, Courtney E.
    Hars, Vera
    Hoke, Eva
    Bloomfield, Clara D.
    Caligiuri, Michael A.
    Larson, Richard A.
    CANCER, 2014, 120 (07) : 1010 - 1017
  • [7] A pilot study of interleukin-2 for adult patients with acute myelogenous leukemia in first complete remission
    Cortes, JE
    Kantarjian, HM
    O'Brien, S
    Giles, F
    Keating, MJ
    Freireich, EJ
    Estey, EH
    CANCER, 1999, 85 (07) : 1506 - 1513
  • [8] Interleukin-2 after autologous stem-cell transplantation for adult patients with acute myeloid leukemia in first complete remission
    Stein, AS
    O'Donnell, MR
    Slovak, ML
    Snyder, DS
    Nademanee, AP
    Parker, P
    Molina, A
    Somlo, G
    Fung, HC
    Krishnan, A
    Rodriguez, R
    Spielberger, RT
    Wang, SR
    Dagis, A
    Vora, N
    Arber, DA
    Niland, JC
    Forman, SJ
    JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (04) : 615 - 623
  • [9] Cost-effectiveness analysis for midostaurin versus standard of care in acute myeloid leukemia in the United Kingdom
    Gabriel Tremblay
    Mike Dolph
    Sachin Patel
    Patricia Brandt
    Anna Forsythe
    Cost Effectiveness and Resource Allocation, 16
  • [10] Cost-effectiveness analysis for midostaurin versus standard of care in acute myeloid leukemia in the United Kingdom
    Tremblay, Gabriel
    Dolph, Mike
    Patel, Sachin
    Brandt, Patricia
    Forsythe, Anna
    COST EFFECTIVENESS AND RESOURCE ALLOCATION, 2018, 16
12345